{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hyaluronidase",
    "query": {
      "intervention": "hyaluronidase"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 167,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=hyaluronidase&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T20:25:25.955Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05995626",
      "title": "Hyaluronidase Via LADD Scleroderma-induced Microstomia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Microstomia",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "CO2 laser",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-03-01",
      "completion_date": "2024-09-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05995626"
    },
    {
      "nct_id": "NCT03301220",
      "title": "A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Daratumumab SC: daratumumab + rHuPH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 390,
      "start_date": "2017-11-07",
      "completion_date": "2026-05-04",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03301220"
    },
    {
      "nct_id": "NCT00774800",
      "title": "Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Humalog",
          "type": "DRUG"
        },
        {
          "name": "Humulin-R",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human hyaluronidase PH20 (rHuPH20)",
          "type": "DRUG"
        },
        {
          "name": "Liquid meal",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2008-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774800"
    },
    {
      "nct_id": "NCT04632992",
      "title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Unresectable or Metastatic Solid Malignancy"
      ],
      "interventions": [
        {
          "name": "Entrectinib",
          "type": "DRUG"
        },
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Investigator's Choice of Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        },
        {
          "name": "Pralsetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 252,
      "start_date": "2021-01-13",
      "completion_date": "2024-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 38,
      "location_summary": "Anchorage, Alaska • Oro Valley, Arizona • Hot Springs, Arkansas + 33 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Oro Valley",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04632992"
    },
    {
      "nct_id": "NCT00773175",
      "title": "Subcutaneous Rehydration Compared to Intravenous Rehydration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dehydration"
      ],
      "interventions": [
        {
          "name": "recombinant human hyaluronidase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "30 Days to 10 Years"
      },
      "enrollment_count": 148,
      "start_date": "2008-10",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-07",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 25,
      "location_summary": "Hartford, Connecticut • Orlando, Florida • Tampa, Florida + 20 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00773175"
    },
    {
      "nct_id": "NCT02059694",
      "title": "Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Upper Eyelid Surgery"
      ],
      "interventions": [
        {
          "name": "Hyaluronidase",
          "type": "DRUG"
        },
        {
          "name": "2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059694"
    },
    {
      "nct_id": "NCT03493854",
      "title": "A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab IV",
          "type": "DRUG"
        },
        {
          "name": "FDC of Pertuzumab and Trastuzumab SC",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab IV",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab SC",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Post-operative Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Hormone Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2018-06-14",
      "completion_date": "2023-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-06-26",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 4,
      "location_summary": "Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Farmington",
          "state": "New Mexico"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Lakewood",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03493854"
    },
    {
      "nct_id": "NCT00386386",
      "title": "Recombinant Hyaluronidase in Out-of-Hospital Setting: The EASI Access Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mass Casualty Incident",
        "Dehydration"
      ],
      "interventions": [
        {
          "name": "hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-13",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00386386"
    },
    {
      "nct_id": "NCT00807963",
      "title": "Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Risk Factors for or a Diagnosis of Osteoporosis"
      ],
      "interventions": [
        {
          "name": "rHuPH20",
          "type": "DRUG"
        },
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Halozyme Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 31,
      "start_date": "2008-12",
      "completion_date": "2009-09-21",
      "has_results": false,
      "last_update_posted_date": "2018-08-15",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00807963"
    },
    {
      "nct_id": "NCT02955355",
      "title": "Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "HYQVIA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2016-11-14",
      "completion_date": "2023-07-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-28",
      "last_synced_at": "2026-09-07T20:25:25.955Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955355"
    }
  ]
}